Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.

abstract：:High-throughput genotyping approaches are being developed to meet the demands of pharmacogenomnics, where numerous individuals are studied with thousands of single nucleotide polymorphism (SNP) markers. All non-gel-based genotyping approaches achieve allelic discrimination by one of four mechanisms: allele-specific hy...

journal_title：Pharmacogenomics

authors： Kwok PY

更新日期：2000-02-01 00:00:00

abstract：AIM:The present study introduces a simple method for CYP2D6 genotyping that not only determines the heterozygous or homozygous deletions and duplications, but also distinguishes tandem hybrids. MATERIALS & METHODS:Using two commercially available methods, 49 Korean male subjects were genotyped for CYP2D6. The Affymetr...

journal_title：Pharmacogenomics

authors： Kim J,Lee SY,Lee KA

更新日期：2012-06-01 00:00:00

abstract：:Incidental findings have long posed challenges for healthcare providers, but the scope and scale of these challenges have increased with the introduction of new technologies. This article assesses the impact of incidental findings on the introduction of prospective pharmacogenomic testing into clinical use. Focusing o...

journal_title：Pharmacogenomics

authors： Brothers KB,Langanke M,Erdmann P

更新日期：2013-08-01 00:00:00

abstract：AIM:We examined whether HLA-DRB1*1501 and four VDR SNPs influence the macrophage response to infection with Mycobacterium tuberculosis (Mtb) via innate immune versus drug treatment or drug delivery mechanisms. MATERIALS & METHODS:Monocyte-derived macrophages from 24 healthy donors were infected with Mtb in vitro. Surv...

journal_title：Pharmacogenomics

authors： Singh AK,Abhimanyu,Yadav AB,Sharma S,Garg R,Bose M,Misra A

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND & METHODS:Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation ...

journal_title：Pharmacogenomics

authors： Mitropoulou C,Fragoulakis V,Bozina N,Vozikis A,Supe S,Bozina T,Poljakovic Z,van Schaik RH,Patrinos GP

更新日期：2015-01-01 00:00:00

abstract：:The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...

journal_title：Pharmacogenomics

authors： Aubrecht J,Caba E

更新日期：2005-06-01 00:00:00

abstract：:Migraine is a paroxysmal neurological disorder affecting up to 6% of males and 18% of females in the general population, and has been demonstrated to have a strong, but complex, genetic component. Genetic investigation of migraine provides hope that new targets for medications and individual specific therapy will be d...

journal_title：Pharmacogenomics

authors： Fernandez F,Colson NJ,Griffiths LR

更新日期：2007-06-01 00:00:00

abstract：AIMS:To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). MATERIALS & METHODS:This was a multicenter prospective study. One hundred and forty four pa...

journal_title：Pharmacogenomics

authors： Tian J,Qin X,Fang K,Chen Q,Hou J,Li J,Yu W,Chen D,Hu Y,Li X

更新日期：2012-05-01 00:00:00

abstract：:Chronic fatigue syndrome (CFS) is prevalent, disabling and costly. Despite extensive literature describing the epidemiology and clinical aspects of CFS, it has been recalcitrant to diagnostic biomarker discovery and therapeutic intervention. This is due to the fact that CFS is a complex illness defined by self-reporte...

journal_title：Pharmacogenomics

authors： Vernon SD,Whistler T,Aslakson E,Rajeevan M,Reeves WC

更新日期：2006-03-01 00:00:00

abstract：AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

journal_title：Pharmacogenomics

authors： Lee KC,Hudmon KS,Ma JD,Kuo GM

更新日期：2015-01-01 00:00:00

abstract：AIMS: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. SUBJECTS & METHODS:Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. RESULTS:Carriers o...

journal_title：Pharmacogenomics

authors： Saab R,Zouk AN,Mastouri R,Skaar TC,Philips S,Kreutz RP

更新日期：2015-11-01 00:00:00

abstract：:Large differences are observed in chemotherapy response between breast cancer patients, with a substantial part of this variability being explained by genetic factors. Polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets influence the pharmacokinetics and pharmacodynamics of th...

journal_title：Pharmacogenomics

authors： González-Neira A

更新日期：2012-04-01 00:00:00

abstract：:The human µ-opioid receptor variant 118 A>G (rs1799971) has become one of the most analyzed genetic variants in the pain field. At the molecular level, the variant reduces opioid receptor signaling efficiency and expression, the latter probably via a genetic-epigenetic interaction. In experimental settings, the varian...

journal_title：Pharmacogenomics

authors： Walter C,Doehring A,Oertel BG,Lötsch J

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:Essential hypertension arises from the combined effect of genetic and environmental factors. A pharmacogenomics approach could help to identify additional molecular mechanisms involved in its pathogenesis. AIM:The aim of SOPHIA study was to identify genetic polymorphisms regulating blood pressure response t...

journal_title：Pharmacogenomics

authors： Frau F,Zaninello R,Salvi E,Ortu MF,Braga D,Velayutham D,Argiolas G,Fresu G,Troffa C,Bulla E,Bulla P,Pitzoi S,Piras DA,Glorioso V,Chittani M,Bernini G,Bardini M,Fallo F,Malatino L,Stancanelli B,Regolisti G,Ferri

更新日期：2014-09-01 00:00:00

abstract：AIMS:Carvedilol is an effective treatment in hypertension and chronic heart failure. The medical impact of polymorphisms in CYP2D6 and in the β-adrenergic receptors ADRB1 and ADRB2 on the pharmacokinetics and pharmacodynamics of carvedilol is controversial. METHODS:After carvedilol 25 mg was administered to 110 volunt...

journal_title：Pharmacogenomics

authors： Sehrt D,Meineke I,Tzvetkov M,Gültepe S,Brockmöller J

更新日期：2011-06-01 00:00:00

abstract：:Fibrates are a medication class prescribed for decades as 'broad-spectrum' lipid-modifying agents used to lower blood triglyceride levels and raise high-density lipoprotein cholesterol levels. Such lipid changes are associated with a decrease in cardiovascular disease, and fibrates are commonly used to reduce risk of ...

journal_title：Pharmacogenomics

authors： House JS,Motsinger-Reif AA

更新日期：2020-03-01 00:00:00

abstract：:The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

journal_title：Pharmacogenomics

authors： Huang S

更新日期：2001-08-01 00:00:00

abstract：:Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS). OCT alleles were investigated in PCOS patients to identify genetic 'bad responders' and 'nonresponders' to metformin including their possible effects on glucose metabolism without treatment. We genotyped eight SNPs in OCT1, OCT2...

journal_title：Pharmacogenomics

authors： Schweighofer N,Lerchbaum E,Trummer O,Schwetz V,Pieber T,Obermayer-Pietsch B

更新日期：2014-02-01 00:00:00

abstract：:Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

journal_title：Pharmacogenomics

authors： Schumacher-Schuh AF,Rieder CR,Hutz MH

更新日期：2014-06-01 00:00:00

abstract：:The potential for personalized sequencing to individually optimize medical treatment in diseases such as cancer and for pharmacogenomic application is just beginning to be realized, and the utility of sequencing healthy individuals for managing health is also being explored. The data produced requires additional advan...

journal_title：Pharmacogenomics

authors： Esplin ED,Oei L,Snyder MP

更新日期：2014-11-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability...

journal_title：Pharmacogenomics

authors： Megías-Vericat JE,Montesinos P,Herrero MJ,Bosó V,Martínez-Cuadrón D,Poveda JL,Sanz MÁ,Aliño SF

更新日期：2016-07-01 00:00:00

abstract：:For the last 40 years, 5-fluorouracil (5-FU) has remained the treatment of choice in both the adjuvant and advanced treatment of colorectal cancer (CRC). However, 5-FU monotherapy produces response rates of only 10-20% in the advanced setting. 5-FU has been combined with newer agents, such as oxaliplatin and irinoteca...

journal_title：Pharmacogenomics

authors： Allen WL,Johnston PG

更新日期：2005-09-01 00:00:00

abstract：:Pancreatic carcinoma is usually diagnosed late when treatment options are limited and is considered a chemo-resistant malignancy. However, early stage, good performance status and specific patient subgroup are thought to have a more favorable prognosis. Search for novel molecular biomarkers, which could predict treatm...

journal_title：Pharmacogenomics

authors： Zemanek T,Melichar B,Lovecek M,Soucek P,Mohelnikova-Duchonova B

更新日期：2019-01-01 00:00:00

abstract：:The efficiency of new generation sequencing methods and the reduction of their cost has led pharmacogenomics to gradually supplant pharmacogenetics, leading to new applications in personalized medicine along with new perspectives in drug design or identification of drug response factors. The amount of data generated i...

journal_title：Pharmacogenomics

authors： Barrot CC,Woillard JB,Picard N

更新日期：2019-06-01 00:00:00

abstract：AIM:We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychot...

journal_title：Pharmacogenomics

authors： Gupta M,Chauhan C,Bhatnagar P,Gupta S,Grover S,Singh PK,Purushottam M,Mukherjee O,Jain S,Brahmachari SK,Kukreti R

更新日期：2009-02-01 00:00:00

abstract：:Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranuloc...

journal_title：Pharmacogenomics

authors： Legge SE,Walters JT

更新日期：2019-03-01 00:00:00

abstract：:In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

journal_title：Pharmacogenomics

authors： Awada Z,Zgheib NK

更新日期：2014-04-01 00:00:00

abstract：:Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...

journal_title：Pharmacogenomics

authors： Johnson JA

更新日期：2013-05-01 00:00:00

abstract：:Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...

journal_title：Pharmacogenomics

authors： Molokhia M,McKeigue P

更新日期：2006-06-01 00:00:00

abstract：:Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...

journal_title：Pharmacogenomics

authors： Herd C

更新日期：2002-01-01 00:00:00